These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Costs and benefits of serum alpha-fetoprotein screening. Read AP. Br Med J; 1987 Apr; 2(6154):1787. PubMed ID: 83895 [No Abstract] [Full Text] [Related]
4. Maternal serum alpha-fetoprotein screening: a cost-benefit analysis. Layde PM, von Allmen SD, Oakley GP. Am J Public Health; 1979 Jun; 69(6):566-73. PubMed ID: 87134 [Abstract] [Full Text] [Related]
5. Midtrimester screening for open neural tube defects: correlation of sonography with amniocentesis results. Lindfors KK, McGahan JP, Tennant FP, Hanson FW, Walter JP. AJR Am J Roentgenol; 1987 Jul; 149(1):141-5. PubMed ID: 2438918 [Abstract] [Full Text] [Related]
6. Maternal serum alpha-fetoprotein screening for neural tube defects. Report of a combined study in Germany and short overview on screening in populations with low birth prevalence of neural tube defects. Fuhrmann W, Weitzel HK. Hum Genet; 1985 Jul; 69(1):47-61. PubMed ID: 2578423 [Abstract] [Full Text] [Related]
7. Maternal serum alpha-fetoprotein screening for the detection of neural tube defects. Crandall BF, Robertson RD, Lebherz TB, King W, Schroth PC. West J Med; 1983 Apr; 138(4):524-30. PubMed ID: 6191442 [Abstract] [Full Text] [Related]
9. The impact of maternal serum alpha fetoprotein screening on open neural tube defect births in north-east Scotland. Thom H, Campbell AG, Farr V, Fisher PM, Hall MH, Swapp GH, Gray ES. Prenat Diagn; 1985 Jul; 5(1):15-9. PubMed ID: 2579374 [Abstract] [Full Text] [Related]
10. Screening for neural-tube defects. Dunn PM. Lancet; 1980 Mar 15; 1(8168 Pt 1):600. PubMed ID: 6153744 [No Abstract] [Full Text] [Related]
11. Establishment of a collaborative university-commercial maternal serum alpha-fetoprotein screening program: a model for tertiary center outreach. Evans MI, Belsky RL, Clementino NA, Shlagor P, Brieger G, Koppitch FC, Syner FN, Rodriguez SE, Sokol RJ. Am J Obstet Gynecol; 1987 Jun 15; 156(6):1441-9. PubMed ID: 2438935 [Abstract] [Full Text] [Related]
12. Predictive values, relative risks, and overall benefits of high and low maternal serum alpha-fetoprotein screening in singleton pregnancies: new epidemiologic data. Milunsky A, Jick SS, Bruell CL, MacLaughlin DS, Tsung YK, Jick H, Rothman KJ, Willett W. Am J Obstet Gynecol; 1989 Aug 15; 161(2):291-7. PubMed ID: 2475017 [Abstract] [Full Text] [Related]
13. Factors influencing the uptake of screening for open neural-tube defects and amniocentesis to test for Down's syndrome. Marteau TM, Johnston M, Shaw RW, Slack J. Br J Obstet Gynaecol; 1989 Jun 15; 96(6):739-41. PubMed ID: 2478187 [No Abstract] [Full Text] [Related]
14. Maternal serum alpha-fetoprotein screening: effects of weight adjustment. Kazazian LC, Niebyl JR, Joseph JM. Am J Obstet Gynecol; 1987 Sep 15; 157(3):782-4. PubMed ID: 2443009 [No Abstract] [Full Text] [Related]
15. Use of alpha-fetoprotein for diagnosis of neural tube and other anomalies. Cowchock S, Jackson L. Clin Obstet Gynaecol; 1980 Apr 15; 7(1):83-102. PubMed ID: 6155238 [No Abstract] [Full Text] [Related]